China Exports Climb to Record High in First Half of 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan
In connection with HekaBio's recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan. Under Japan's Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class forerunner for the treatment of several intractable neurodegenerative diseases. SANTA ANA, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) ('NKGen' or the 'Company'), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer ('NK') cell therapeutics, and HekaBio K.K., headquartered in Chuo-ku, Tokyo ('HekaBio'), announced a strategic partnership to accelerate the regulatory, manufacturing and commercial development of NKGen's autologous NK cell therapy, troculeucel, in Japan following HekaBio's recently announced investment in common equity of NKGen. HekaBio will lead all clinical trials in Japan and oversee all regulatory activities with Japan's Pharmaceuticals and Medical Devices Agency for pre-market approval of troculeucel in several neurodegenerative disease indications, including Alzheimer's and Parkinson's Diseases. As troculeucel is an autologous, non-genetically modified cell therapy, there is allowance under regenerative medicine regulations in Japan to offer this therapy to patients on an accelerated path, much faster than in other major markets. HekaBio will fully leverage the regulation and its domestic strategic partner network, aiming for first dosing in Japanese patients over the next 12 months. Beyond intractable disease, troculeucel has the potential to also support Japan's aging population in the longevity/wellness space. 'Japan has always had an advanced progressive health care system where great attention has been placed on the use of novel autologous cell therapies for prevention, longevity, and wellness as well as for the treatment of more chronic illnesses,' said Paul Y. Song, MD, Chairman and Chief Executive Officer ('CEO') of NKGen. 'I am convinced that HekaBio's clinical, regulatory, and commercial expertise will guide us to satisfy all regulatory requirements, find the best local manufacturing partner to make our therapy readily available, and ultimately develop the best commercial strategy for Japan. We are very excited to partner with HekaBio.' 'Dementia, particularly Alzheimer's Disease, and other neurodegenerative diseases together present significant health and social challenges in Japan due to the country's aging population. We are very excited about our partnership with NKGen and look forward to advancing troculeucel for the benefit of patients and society,' said Rob Claar, CEO of HekaBio. About NKGen Biotech NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit About Troculeucel Troculeucel is a novel cell-based, patient specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate. NKGen is developing troculeucel for the treatment of neurodegenerative disorders and a broad range of cancers. Troculeucel is the International Nonproprietary Name ('INN') for SNK01 assigned by the World Health Organization ('WHO'). The WHO INN approval of troculeucel establishes a universally recognized nonproprietary drug name for SNK01 and marks a significant step on NKGen's journey toward bringing this therapy to market. About HekaBio HekaBio is a Japan-based healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage yet de-risked opportunities in CNS, oncology and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, please visit Forward-Looking Statements Statements contained in this press release may contain 'forward-looking statements' within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'could', 'continue', 'expect', 'estimate', 'may', 'plan', 'outlook', 'future' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the Company's plans and expected timing for developing troculeucel and SNK02, including the expected timing of completing and announcing further results from its ongoing clinical studies; and the Company's expected timing for developing its product candidates and potential benefits of its product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the Company's ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical study do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; the risk that the abstract will not be published as planned including delays in timing, format, or accessibility; and NKGen's ability to raise additional funding to complete the development of its product candidates. These and other risks and uncertainties are described more fully under the caption 'Risk Factors' and elsewhere in the Company's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission's website at and on the Company's website under the subheading 'Investors—Financial and Filings'. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Internal Contact: Denise Chua, MBA, CLS, MLS (ASCP)SVP, Corporate Affairs949-396-6830dchua@ External Contact: Kevin GardnerManaging DirectorLifeSci Advisors, LLCkgardner@
Yahoo
5 minutes ago
- Yahoo
Netflix earnings top estimates as company raises full-year revenue forecast
Netflix (NFLX) reported earnings that beat expectations on both the top and bottom lines as the company simultaneously raised its full-year revenue guidance. Here's what Netflix reported for the second quarter compared to Bloomberg consensus estimates. Revenue: $11.08 billion versus $11.06 billion expected and $9.56 billion last year; Netflix's guidance: $11.04 billion Earnings per share: $7.19 versus $7.09 expected and $4.88 last year; Netflix's guidance: $7.03 The company guided to revenue for the current quarter above Wall Street expectations, forecasting Q3 revenue of $11.53 billion compared to the $11.28 billion analysts polled by Bloomberg had expected. Earnings are also expected to exceed expectations for the quarter. The company sees $6.87 a share compared to analyst estimates of $6.70. For full-year 2025, the company said it now expects revenue between $44.8 billion to $45.2 billion, ahead of its prior forecast of $43.5 billion to $44.5 billion. "The majority of the increase in our revenue forecast reflects the recent depreciation of the US dollar vs. most other currencies, with the balance attributable to continued business momentum driven by solid member growth and ad sales," the company said in the release. Netflix expects revenue from its ads business to roughly double to about $3 billion in 2025. The reports comes as shares have soared over 40% since the start of the year, with the stock's valuation a top debate on Wall Street as the streamer doubles down on live events and sports content. As a reminder, the company stopped reporting subscriber numbers last quarter. At the end of 2024, the company had 301.6 million global subscribers. Netflix said in its fourth quarter shareholder letter it will disclose subscriber data in the future "as we cross key milestones." Executives have pointed to the ad-supported tier as a longer-term driver of user growth. Earlier this year, Netflix hiked prices across several plans in the US, including the ad plan, which still remains one of the cheapest tiers on the market at $7.99 per month. In May, Netflix announced its ad-supported tier has reached 94 million global monthly active users, an increase from 70 million in November. The company also noted strong engagement among US ad-tier members, who are watching approximately 41 hours of content per month, on par with those on the ad-free plan. Looking ahead, Netflix boasts a strong second-half content slate, including new seasons of tentpole series like "Wednesday," "Stranger Things," and "Squid Game," which premiered its latest installment last month. Among major streaming platforms, Netflix continues to lead with the lowest subscriber churn, suggesting high user stickiness. Additionally, live events and sports programming, such as the recent Taylor vs. Serrano fight, upcoming NFL Christmas Day games, and weekly WWE Raw, could further boost engagement, attract ad dollars, and support subscriber growth. Speculation has also been building around whether the UFC could be the next major sports property to land on Netflix. Heading into the report, Wall Street analysts have remained divided over Netflix's valuation, with shares currently trading at roughly 40 times forward earnings, a notable premium compared to the broader market and even some of the company's tech peers. Allie Canal is a Senior Reporter at Yahoo Finance. Follow her on X @allie_canal, LinkedIn, and email her at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
Dollar Gains as Traders Turn Focus to Signs of Economic Strength
(Bloomberg) -- The dollar strengthened Thursday and was poised for a second week of gains, after reports on consumer spending and the labor market added to signs of resilience in the US economy. The Dutch Intersection Is Coming to Save Your Life Advocates Fear US Agents Are Using 'Wellness Checks' on Children as a Prelude to Arrests LA Homelessness Drops for Second Year Manhattan, Chicago Murder Rates Drop in 2025, Officials Say A gauge of the currency's performance against global peers settled 0.3% higher with the greenback strengthening against the euro, yen and the pound. Retail sales for June came in stronger than expected and weekly initial jobless claims were below estimates, signals that the economy is holding up even as some fret over the impact of President Donald Trump's tariffs. Traders now see the likelihood of an interest-rate cut at September's Federal Reserve meeting as a coin toss, whereas it was previously seen as a lock. 'The market has refocused on the narrative of a resilient US economy with burgeoning inflation pressures,' said Aroop Chatterjee, a strategist at Wells Fargo. 'Market pricing for Fed cuts continues to decline.' Yields across most US Treasuries rose Thursday in a choppy session. Yields on two-year notes, which are most sensitive to changes in monetary policy, rose three basis points to 3.92%. Thursday's gains for the dollar marked a rebound from the previous session, in which it slumped after Trump floated the idea of firing Fed Chair Jerome Powell. It's now up 0.7% this week, on track to close out its second weekly gain for the first time since May. An hour after those reports, Trump walked back the threat, calming a brief outbreak of volatility in markets. Still, the latest escalation spooked investors over the prospect of political interference at the central bank. 'Any central bank's biggest asset is its credibility, so if that were to go, through a firing, the market will take it very badly,' Kokou Agbo-Bloua, Societe Generale SA's global head of economics & cross-asset research, told Bloomberg TV, adding that speculation about a replacement would increase swings in US asset prices and weaken the dollar. Concerns over that situation are expected to continue hanging over markets and put pressure on the dollar and Treasuries, said George Saravelos, global head of FX research at Deutsche Bank AG. 'This underlying story, so long as it lingers, it will act as a big headwind both to the dollar and to fixed income, until it gets resolved one way or another,' he told Bloomberg TV. For now, better-than-expected US data has supported the greenback, said Yusuke Miyairi, a foreign-exchange strategist at Nomura. While investors had expected tariffs to hurt the US economy, 'the US data haven't shown any strong indication of growth weakness,' Miyairi said. Treasuries Meanwhile, activity in the options linked to the Secured Overnight Financing Rate, which closely tracks Fed policy expectations, showed traders looking to hedge the possibility that the Fed will cut rates at a faster pace or to a greater degree than the market has priced in. The volumes over Wednesday's session in SOFR futures topped six million for the first time in about six weeks as traders looked to re-position around the news. Chief economist at Apollo Management Torsten Slok believes the market is overpricing the chances of further reductions this year, as the Fed will have to assess the inflationary impact of tariffs and deportations. 'The market is way, way too eager to price in cuts,' he told Bloomberg TV. Slok sees one rate cut by the end of the 2025, while the market is leaning to two cuts. --With assistance from Isabella Ward, Ye Xie and George Lei. (Recasts with dollar's performance.) How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All What the Tough Job Market for New College Grads Says About the Economy Forget DOGE. Musk Is Suddenly All In on AI The Quest for a Hangover-Free Buzz How Hims Became the King of Knockoff Weight-Loss Drugs ©2025 Bloomberg L.P.
